Jade Biosciences, Inc.（JBIO）内部人交易：高管与董事近期交易
过去 18 个月，共有 13 位内部人为 Jade Biosciences, Inc.（JBIO）报告了 14 笔 Form 4 交易（最近一笔 2026-02-13）。
| 日期 | 内部人 | 职务 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-02-13 | King Andrew James | Chief Scientific Officer & Head of Research and Development | 买入 | 41,250 | $0 |
| 2026-02-13 | Dahms Bradford D. | Chief Financial Officer | 买入 | 37,813 | $0 |
| 2026-02-13 | Frohlich Tom | Chief Executive Officer | 买入 | 78,750 | $0 |
| 2026-02-13 | Balta Elizabeth | Chief Legal Officer and Corporate Secretary | 买入 | 28,125 | $0 |
| 2025-10-08 | Harwin Peter Evan | 董事 | 买入 | 1.3M | $12.2M |
| 2025-10-08 | Fairmount Healthcare Fund II L.P. | 董事 | 买入 | 1.3M | $12.2M |
| 2025-10-08 | Fairmount Funds Management LLC | 董事 | 买入 | 1.3M | $12.2M |
| 2025-10-08 | Kiselak Tomas | 董事 | 买入 | 1.3M | $12.2M |
| 2025-10-08 | Fairmount Healthcare Co-Invest IV L.P. | 董事 | 买入 | 1.3M | $12.2M |
| 2025-05-19 | Frohlich Tom | Chief Executive Officer | 买入 | 6,000 | $44,400 |
| 2025-04-30 | RA Capital Healthcare Fund LP | 10% 以上股东 | 买入 | 1.1M | $0 |
| 2025-04-30 | RA CAPITAL MANAGEMENT, L.P. | 10% 以上股东 | 买入 | 1.1M | $0 |
| 2025-04-30 | Kolchinsky Peter | 10% 以上股东 | 买入 | 1.1M | $0 |
| 2025-04-30 | Shah Rajeev M. | 10% 以上股东 | 买入 | 1.1M | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-02-13